VVY — Vivoryon Therapeutics NV Income Statement
0.000.00%
Last trade - 00:00
- €11.76m
- -€30.44m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 10.8 | 0 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 9.2 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7.7 | 7.71 | 16 | 23.6 | 29.1 |
Operating Profit | -7.7 | -7.71 | -16 | -12.8 | -29.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.74 | -7.82 | -16.5 | -12.2 | -28.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.74 | -7.82 | -16.5 | -12.7 | -28.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.74 | -7.82 | -16.5 | -12.7 | -28.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.74 | -7.82 | -16.5 | -12.7 | -28.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.924 | -0.392 | -0.827 | -0.633 | -1.28 |
Dividends per Share |